ATP6V0B | ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b | Predicted membrane proteins
| | | | | Expressed in all |
ATP6V0C | ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c | Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
ATP6V0D1 | ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 | Plasma proteins Predicted intracellular proteins Transporters
| | | | | Expressed in all |
ATP6V0D2 | ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 | Predicted intracellular proteins
| | | | | Tissue enriched |
ATP6V0E1 | ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 | Predicted membrane proteins
| | | | | Expressed in all |
ATP6V0E2 | ATPase, H+ transporting V0 subunit e2 | Predicted membrane proteins
| | | | | Expressed in all |
ATP6V1A | ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A | Enzymes Plasma proteins Predicted intracellular proteins Transporters
| | | | | Expressed in all |
ATP6V1B1 | ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 | Disease related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
ATP6V1B2 | ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 | FDA approved drug targets Predicted intracellular proteins Transporters
| | | | | Expressed in all |
ATP6V1C1 | ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 | Predicted intracellular proteins Transporters
| | | | | Expressed in all |
ATP6V1C2 | ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C2 | Predicted intracellular proteins Transporters
| | | | | Tissue enhanced |
ATP6V1D | ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D | Predicted intracellular proteins
| | | | | Expressed in all |
ATP6V1E1 | ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 | Plasma proteins Predicted intracellular proteins Transporters
| | | | | Expressed in all |
ATP6V1E2 | ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E2 | Predicted intracellular proteins
| | | | | Tissue enriched |
ATP6V1F | ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F | Predicted intracellular proteins Transporters
| | | | | Expressed in all |
ATP6V1G1 | ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 | Plasma proteins Predicted intracellular proteins Transporters
| | | | | Expressed in all |
ATP6V1G2 | ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G2 | Predicted intracellular proteins
| | | | | Tissue enriched |
ATP6V1G3 | ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G3 | Predicted intracellular proteins Transporters
| | | | | Tissue enriched |
ATP6V1H | ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H | Predicted intracellular proteins Transporters
| | | | | Expressed in all |
BAIAP2L1 | BAI1-associated protein 2-like 1 | Predicted intracellular proteins
| | | | | Mixed |
BCAR1 | Breast cancer anti-estrogen resistance 1 | Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Mixed |
BDH1 | 3-hydroxybutyrate dehydrogenase, type 1 | Candidate cardiovascular disease genes Enzymes Mitochondrial proteins Predicted intracellular proteins
| | | | | Expressed in all |
BIRC5 | Baculoviral IAP repeat containing 5 | Cancer-related genes Predicted intracellular proteins
| | | | | Mixed |
BMP8A | Bone morphogenetic protein 8a | Predicted secreted proteins
| | | | | Tissue enriched |
BRSK2 | BR serine/threonine kinase 2 | Enzymes Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
BSCL2 | Berardinelli-Seip congenital lipodystrophy 2 (seipin) | Disease related genes Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CAB39 | Calcium binding protein 39 | Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CAB39L | Calcium binding protein 39-like | Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1D | Calcium channel, voltage-dependent, L type, alpha 1D subunit | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1E | Calcium channel, voltage-dependent, R type, alpha 1E subunit | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CACNA2D2 | Calcium channel, voltage-dependent, alpha 2/delta subunit 2 | FDA approved drug targets Predicted intracellular proteins Transporters
| | | | | Tissue enriched |
CAMK2G | Calcium/calmodulin-dependent protein kinase II gamma | Enzymes Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CARTPT | CART prepropeptide | FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CCL2 | Chemokine (C-C motif) ligand 2 | Cancer-related genes Candidate cardiovascular disease genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
CCL5 | Chemokine (C-C motif) ligand 5 | Cancer-related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CD38 | CD38 molecule | Cancer-related genes CD markers Enzymes Predicted intracellular proteins
| | | | | Mixed |
CDK1 | Cyclin-dependent kinase 1 | Cancer-related genes Enzymes Plasma proteins Predicted intracellular proteins
| | | | | Mixed |
CDK16 | Cyclin-dependent kinase 16 | Enzymes Predicted intracellular proteins
| | | | | Expressed in all |
CEP19 | Centrosomal protein 19kDa | Disease related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
CHRM3 | Cholinergic receptor, muscarinic 3 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
CITED1 | Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1 | Predicted intracellular proteins
| | | | | Tissue enriched |
CLOCK | Clock circadian regulator | Enzymes Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
CNR1 | Cannabinoid receptor 1 (brain) | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CPEB1 | Cytoplasmic polyadenylation element binding protein 1 | Predicted intracellular proteins
| | | | | Tissue enhanced |
CPEB2 | Cytoplasmic polyadenylation element binding protein 2 | Predicted intracellular proteins
| | | | | Expressed in all |
CPLX1 | Complexin 1 | Predicted intracellular proteins
| | | | | Tissue enriched |
CPLX3 | Complexin 3 | Predicted intracellular proteins
| | | | | Tissue enhanced |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |